Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03087890
Other study ID # REK2015/540
Secondary ID TZ16CT007NIMRlHQ
Status Completed
Phase Phase 4
First received
Last updated
Start date March 30, 2017
Est. completion date July 25, 2019

Study information

Verified date October 2019
Source University of Bergen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cotrimoxazole preventive therapy (CPT) is recommended for prevention of morbidity and mortality due to Pneumocystis pneumonia and other infections in HIV positive patients with low immunity. Common clinical practice is to start CPT in any patient with CD4 counts below 200/µL, and, conversely, to stop CPT when immunity has been restored by antiretroviral treatment to CD4 counts above 200/µL or when viral suppression has been documented for 3 months. However, the latest WHO guidelines widely expands the indication for CPT by advocating for settings with high prevalence of malaria and bacterial infections, that all patients with HIV start CPT regardless of CD4 counts and clinical stage. Furthermore, WHO recommends these patients to continue CPT indefinitely regardless of evidence of immune restoration (The recommendation is for settings with high prevalence of malaria and bacterial infections, not for high-income countries). There is limited scientific evidence to recommend prolonged CPT, as studies have shown it is associated with modestly reduced morbidity due to pneumonia, meningitis and malaria, but no corresponding reduction in mortality. The impact of such a large increase in antibiotic use on the emergence of antimicrobial resistance has not been thoroughly considered. Our previous studies in Tanzania showed that multidrug-resistant bacteria frequently cause bloodstream infections with resultant very high case-fatality rates. As genes encoding for multiple antibiotic resistance traits are transferred by plasmids together with resistance towards cotrimoxazole, prolonged CPT will likely favor the selection of carriage of multidrug-resistant gut bacteria. The proposed randomized clinical trial is designed to assess whether prolonged CPT in HIV-positive patients results in increased fecal carriage of multi-drug resistant gut microbes or increased nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA). Secondary endpoints are morbidity (clinical events, hospitalizations) and mortality. Stool specimens, nasal swabs and clinical data will be collected from persons attending voluntary counseling and testing facilities and HIV-clinics in Dar es Salaam, Tanzania. The study results may have important impact on public health in terms of assisting development of rational recommendations for CPT use, and may help prevent emerging antibiotic resistance.


Description:

Background Bacterial infections account for a large proportion of global morbidity and mortality. While antimicrobial drugs have helped save millions from the consequences of these infections, emerging antimicrobial resistance now threatens to reverse those gains. The HIV-epidemic renders large populations drastically more susceptible to bacterial infections, particularly in Sub-Saharan Africa, where HIV is rampant and health-systems to deal with the consequences are insufficient. Indiscriminate use of antimicrobials is thought to be the main driving force behind emerging resistance. The opportunistic infection Pneumocystis jirovecii pneumonia (PJP) is a major cause of mortality among HIV-infected people with low immunity. Continuous cotrimoxazole preventive therapy (CPT) has proved to reduce morbidity and mortality from PJP globally, as well as in Africa where the burden of HIV is largest. The impact of this large-scale antibiotic use on emergence of antimicrobial resistance in Africa remains unclear. In a recent literature review, Sibanda and colleagues found only two studies specifically designed to answer the question of whether CPT induced resistance in common bacterial pathogens, and 15 other studies that assessed the question as sub-analyses of studies designed for other purposes. The two targeted studies both assessed resistance in pneumococci, one finding increased resistance to clindamycin in the CPT group, neither finding any difference in resistance to penicillin. While most of the other 15 studies assessed penicillin-resistance in pneumococci and methicillin-resistance in Staphylococcus aureus (MRSA), only two studies evaluated the effect on Gram-negative bacteria. Among these, the study from San Francisco showed significantly higher temporal increase from 1988 to 1995 in resistance to cotrimoxazole, ampicillin, cefazolin and gentamicin in clinical isolates of E. coli from HIV-positives than from HIV-negatives. The study of HIV-infected children with pneumonia in Cape Town did not find any association between CPT and resistance in clinical isolates, including 26 isolates of Klebsiella pneumonia, the most prevalent Gram-negative microbe in this study. In previous research in Tanzania, we found that multi-drug resistance in Gram-negative bacteria is prevalent and a problem of major public health concern, as invasive infections with such bacteria was associated with a large increase in mortality. Our study found case-fatality rates (>70%) approaching those of the pre-antibiotic era in systemic bacterial infections with multi-resistant Gram-negative bacteria harboring extended-spectrum beta-lactamase (ESBL) resistance. ESBLs are enzymes that render the all-important antibiotics, penicillins and cephalosporins, useless. We also confirmed previous findings that case-fatality rates from bacterial sepsis was higher in HIV-infected than HIV-negative patients. Most disturbingly, our study confirmed that in multidrug-resistant Gram-negative bacteria the gene encoding for ESBL resistance was transferred by plasmids together with resistance to several other antibiotics, including cotrimoxazole. Thus, it is plausible that widespread cotrimoxazole use could lead to selection of multidrug-resistant Gram-negative bacteria in the gut of HIV-patients, which consequently could contribute to the rapid spread of these harmful and difficult-to-treat bacteria. In high-resource countries, it has been shown that CPT can safely be discontinued when CD4 counts increase beyond 200/uL. Recent studies from Sub-Saharan Africa indicate that prolonged CPT after immune restoration to CD4 counts > 200/µL by antiretroviral treatment (ART) may be beneficial as it is associated with reduced hospitalization from malaria and bacterial infections in children. There was, however, no difference in mortality among those who stopped and continued CPT. In the "2014 supplement to the WHO guidelines on the use of antiretroviral drugs for treating and preventing HIV infection", the recommendation for CPT use is widely expanded for settings with high prevalence of malaria and bacterial infections, where it is recommended that all patients with HIV start CPT regardless of CD4 counts and clinical stage and receive prolonged CPT for indefinitely time. Tanzanian national guidelines recommend discontinuing CPT when patients are stabilized with CD4 counts >350/µL, which is a more extensive recommendation than European guidelines, but much less extensive than the WHO recommendations for "settings with high prevalence of malaria and bacterial infections".

Cotrimoxazole has been widely used for a number of different indications and, as a result, cotrimoxazole resistance in general has increased. Given the limited published data on these important public health issues, we designed this study to address the potential impact of prolonged CPT on antimicrobial resistance development with particular focus on Gram-negative gut microbes, VRE (vancomycin-resistant enterococci), and nasal carriage of MRSA. If the study should confirm a marked increase in carriage of multidrug-resistant bacteria in patients on prolonged CPT this needs to be considered when developing new guidelines. We also aim at assessing whether restoration of immunity by ART could be a way to counteract this threat of antimicrobial resistance. This proposed randomized clinical trial will be performed in the setting of the ongoing Dar es Salaam - Bergen collaborative initiative and will include local investigators and laboratory workers, along with Norwegian investigators with scientific experience from clinical and molecular studies in Tanzania.

Problem statement/ research gap CPT has been standard of care for preventing PJP and other infections among HIV-infected patients with CD4 counts < 200µL since the early 1990s. The recent recommendation by WHO to give CPT indefinitely to HIV-infected people in resource-constrained settings, even to those with initial good immunity (CD4 counts above 350/µL) and to those whose immunity has been restored by antiretroviral treatment, would lead to a massive increase in cotrimoxazole consumption in Sub-Saharan Africa, which has the largest burden of HIV-infection. While this recommendation is based on limited scientific data regarding short-term morbidity, there is no evidence of improved survival and the potential harmful implication for selection of multidrug-resistant bacteria in HIV-patients on prolonged CPT has not been comprehensively studied.

Rationale of the study Continuing CPT indefinitely stable good immunity with CD4 counts >350/µL has been shown to reduce morbidity, but not mortality, in persons living with HIV in resource-constrained settings. Complying with recommendation for continuation of CPT indefinitely in patients with restored immunity and virological control would imply a massively increased consumption of cotrimoxazole in HIV-endemic countries. The risk of increased carriage of multidrug-resistant bacteria among HIV-patients on prolonged CPT has not been comprehensively studied, but has potentially grave implications for public health, since systemic infections with these resistant bacteria are very difficult to treat and associated with very high mortality rates. The current study is designed to assess whether prolonged CPT is associated with increased carriage of multidrug-resistant bacteria. The results of this study may have important implications for development of new guidelines on CPT use for resource-constrained settings and may help preventing emerging antibacterial resistance.


Recruitment information / eligibility

Status Completed
Enrollment 537
Est. completion date July 25, 2019
Est. primary completion date July 25, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Only patients who provide written informed consent will be included

- Patients aged 18 years or older with newly diagnosed HIV-infection and CD4 counts of = 350 per microliter will be included for randomisation to receive placebo or cotrimoxazole preventive treatment.

- Persons testing hiv negative at the participating clinics will be included as additional control group but not randomised to interventions

- Persons testing hiv-positive and having impaired immunity with CD4 count below will be included as additional control group but not randomised for intervention. This group will routinely receive cotrimoxazole prophylaxis from the national AIDS control program, and not followed-up further in this study.

Exclusion Criteria:

- CD4<350 per microliter at enrollment

- Patients allergic to cotrimoxazole

- Children under age of 18 years

- Pregnant women

Study Design


Intervention

Drug:
Cotrimoxazole
Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
Placebo
Patients will receive 2 tablets placebo daily for 48 weeks

Locations

Country Name City State
Tanzania Amana Regional Referral Hospital Dar es Salaam
Tanzania Mbagala District Hospital Dar es Salaam
Tanzania Mnazimmoja Health Centre Dar Es Salaam
Tanzania Mwananyamala Regional Referral Hospital Dar es Salaam
Tanzania Pasada Upendano Dar es Salaam
Tanzania Temeke Regional Referral Hospital Dar es Salaam

Sponsors (4)

Lead Sponsor Collaborator
University of Bergen Haukeland University Hospital, Helse Vest, Muhimbili University of Health and Allied Sciences

Country where clinical trial is conducted

Tanzania, 

References & Publications (14)

Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999 May 1;353(9163):1463-8. — View Citation

Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, Fataki M, Msangi V, Tellevik MG, Maselle SY, Langeland N. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol. 2005 Feb;43(2):745-9. — View Citation

Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DS, Jureen R, Msangi V, Tellevik MG, Holberg-Petersen M, Harthug S, Maselle SY, Langeland N. Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis. 2007 May 22;7:43. — View Citation

Blomberg B, Mwakagile DS, Urassa WK, Maselle SY, Mashurano M, Digranes A, Harthug S, Langeland N. Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania. BMC Public Health. 2004 Oct 11;4:45. — View Citation

Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text. — View Citation

Furrer H, Opravil M, Rossi M, Bernasconi E, Telenti A, Bucher H, Schiffer V, Boggian K, Rickenbach M, Flepp M, Egger M; Swiss HIV Cohort Study. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. AIDS. 2001 Mar 9;15(4):501-7. — View Citation

Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M, Nsofwa M, Chalwe V, Mwananyanda L, Mukwamataba D, Malilwe B, Champo D, Macleod WB, Thea DM, Hamer DH. Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study. Bull World Health Organ. 2008 Dec;86(12):929-38. — View Citation

Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K, Williamson J, Shi YP, Feikin DR, Marston B, Brooks JT, Poe A, Zhou Z, Ochieng B, Mintz E, Slutsker L. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg. 2008 Sep;79(3):320-30. — View Citation

Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis. 1999 Dec;180(6):1809-18. — View Citation

Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza F, Culver D, Kizito F, Bunnell R, Kigozi A, Nakanjako D, Wafula W, Quick R. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004 Oct 16-22;364(9443):1428-34. — View Citation

Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis. 2011 May;52(9):1184-94. doi: 10.1093/cid/cir067. Review. — View Citation

Tellevik MG, Sollid JE, Blomberg B, Jureen R, Urassa WK, Langeland N. Extended-spectrum beta-lactamase-type SHV-12-producing Enterobacteriaceae causing septicemia in Tanzanian children: vectors for horizontal transfer of antimicrobial resistance. Diagn Microbiol Infect Dis. 2007 Nov;59(3):351-4. Epub 2007 Sep 18. — View Citation

Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R, Courtielle O, Kirpach P, Mwale B, Salaniponi FM. Changes in Escherichia coli resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole prophylaxis in Thyolo, Malawi. Trans R Soc Trop Med Hyg. 2002 Mar-Apr;96(2):202-4. — View Citation

Zar HJ, Hanslo D, Hussey G. The impact of HIV infection and trimethoprim-sulphamethoxazole prophylaxis on bacterial isolates from children with community-acquired pneumonia in South Africa. J Trop Pediatr. 2003 Apr;49(2):78-83. doi: 10.1093/tropej/49.2.78. — View Citation

* Note: There are 14 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Difference in carriage of resistant bacteria in gut and/or nose between HIV positive patients and HIV negative controls Difference in the proportion who carry antibiotic-resistant bacteria, including presence of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria or vancomycin-resistant enterococci (VRE) on microbiological examination of fecal swab, or methicillin-resistant Staphylococcus aureus (MRSA) on microbiological examination of nasal swab, between HIV positive patients and HIV negative controls At baseline
Other Difference in carriage of resistant bacteria in gut and/or nose between HIV positive patients with CD4 counts above and below 350 Difference in the proportion who carry antibiotic-resistant bacteria, including presence of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria or vancomycin-resistant enterococci (VRE) on microbiological examination of fecal swab, or methicillin-resistant Staphylococcus aureus (MRSA) on microbiological examination of nasal swab, between HIV positive patients with CD4 counts above and below 350 At baseline
Primary Change in carriage of resistant bacteria in gut and/or nose by week 2 Change in the proportion who carry antibiotic-resistant bacteria, including presence of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria or vancomycin-resistant enterococci (VRE) on microbiological examination of fecal swab, or methicillin-resistant Staphylococcus aureus (MRSA) on microbiological examination of nasal swab, from baseline to day 14 From baseline to day 14
Primary Change in carriage of resistant bacteria in gut and/or nose by week 24 Change in the proportion who carry antibiotic-resistant bacteria, including presence of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria or vancomycin-resistant enterococci (VRE) on microbiological examination of fecal swab, or methicillin-resistant Staphylococcus aureus (MRSA) on microbiological examination of nasal swab, from baseline to week 24 From baseline to week 24
Primary Change in carriage of resistant bacteria in gut and/or nose by week 48 Change in the proportion who carry antibiotic-resistant bacteria, including presence of extended-spectrum beta-lactamase (ESBL) producing gram-negative bacteria or vancomycin-resistant enterococci (VRE) on microbiological examination of fecal swab, or methicillin-resistant Staphylococcus aureus (MRSA) on microbiological examination of nasal swab, from baseline to week 48 From baseline to week 48
Secondary Adverse events Adverse events graded as a) light, b) moderate, c) severe, d) life-threatening or e) fatal will be registered through patients' monthly visits to clinic and additional follow-up as required From baseline to 48 weeks
Secondary Mortality All cause mortality From baseline to 48 weeks
Secondary Morbidity Documented episode of malaria, pneumonia, diarrhea and hospital admission From baseline to 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Completed NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4